Gustavo A. Fonseca

Hematology | Oncology

521 N Lecanto Hwy
Lecanto, FL 34461

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Understanding Cancer Clinical Trial Participation in Rural Communities: A Qualitative Focus Group Study.

Understanding Cancer Clinical Trial Participation in Rural Communities: A Qualitative Focus Group Study.

Journal: Psycho-oncology

Published: April 23, 2026

Treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents in a large US community oncology practice: a retrospective chart review.

Treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents in a large US community oncology practice: a retrospective chart review.

Journal: Journal of medical economics

Published: September 02, 2025

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.

Journal: Blood

Published: February 18, 2025

Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014.

Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014.

Journal: Clinical lymphoma, myeloma & leukemia

Published: May 10, 2024

Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.

Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.

Journal: Leukemia & lymphoma

Published: February 08, 2022

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.

Journal: Blood advances

Published: April 30, 2021

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.

Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 08, 2021

Invasive Lobular Breast Carcinoma Can Be a Challenging Diagnosis Without the Use of Tumor Markers.

Invasive Lobular Breast Carcinoma Can Be a Challenging Diagnosis Without the Use of Tumor Markers.

Journal: Cureus

Published: July 07, 2020

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.

Journal: Blood

Published: June 12, 2020

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.

Journal: Leukemia

Published: January 09, 2020

Showing 1-10 of 10

Last Updated: 09/26/2026